DamonRReedMD

Pediatric Hematology & Oncology • New York, NY

Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology

Member, Memorial Hospital Memorial Sloan Kettering Cancer Center Solid Tumor Division Director, MSK Kids President, Connective Tissue Oncology Society Vice Chair, Bone Tumor Committee, COG

Join to view full profile

Dr. Reed is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reed's full profile

Already have an account?

Office
160 East 53rd Street
New York, NY 10022

Summary

Dr. Damon Reed is a pediatric and AYA hematologist/oncologist in New York, NY

Education & Training

University of TennesseeFellowship, Pediatric Hematology/Oncology, 2005 - 2008
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2002 - 2005
Case Western Reserve University School of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2008 - 2026
NY State Medical License 2023 - 2025
TN State Medical License 2005 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
Active, not recruiting
Phase 2
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Start of enrollment: 2016 Oct 25
Active, not recruiting
Phase 2
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Start of enrollment: 2018 Jun 04
Active, not recruiting
Phase 1
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Start of enrollment: 2019 Oct 03
Active, not recruiting
Phase 1, Phase 2
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Start of enrollment: 2019 Sep 27
Completed
Phase 1
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board Start of enrollment: 2020 May 05
Recruiting
Evolutionary Therapy for Rhabdomyosarcoma Start of enrollment: 2020 Sep 27
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

40 citations
Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma
Diana Yu, Elliot Kahen, Christopher L. Cubitt, Jeremy J. McGuire, Jenny Kreahling
Scientific Reports. 2015-11-25
201 citations
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Peter F. Coccia, Alberto S. Pappo, Lynda K. Beaupin, Virginia F. Borges, Scott C. Borinstein
Journal of the National Comprehensive Cancer Network. 2018-01-01
815 citations
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein Abdul-Hassan Tawbi, Melissa Amber Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze
The Lancet. Oncology. 2017-11-01

Press Mentions

Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical TrialJuly 29th, 2020
SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing SarcomaDecember 16th, 2019
Shortage of Critical Cancer Drug Forcing Some Children to Go WithoutOctober 21st, 2019
Join now to see all